KILITCH DRUGS share price has zoomed 6% and is presently trading at Rs 362.0.
Meanwhile, the BSE HEALTHCARE index is at 43,775.5 (up 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are FDC (up 6.1%) and LAURUS LABS (up 3.8%).
NARAYANA HRUDAYALAYA (down 1.8%) and ERIS LIFESCIENCES (down 1.7%) are among the top losers today.
Over the last one year, KILITCH DRUGS has moved up from Rs 201.2 to Rs 362.0, registering a gain of Rs 160.8 (up 79.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,357.7 to 43,775.5, registering a gain of 54.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 135.8%), Jubilant Pharmova (up 126.1%) and GRANULES INDIA (up 119.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,815.6 (up 0.3%).
The top gainers among the BSE Sensex today are Infosys (up 1.5%) and Bharti Airtel (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 25,024.6 (up 0.4%). Divis Laboratories and LTIMINDTREE are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,880.5 to 81,815.6, registering a gain of 15,935.0 points (up 24.2%).
KILITCH DRUGS net profit fell 96.3% YoY to Rs 1 million for the quarter ended June 2024, compared to a profit of Rs 31 million a year ago. Net sales declined 8.5% to Rs 335 million during the period as against Rs 366 million in April-June 2023.
For the year ended March 2023, KILITCH DRUGS reported 33.3% increase in net profit to Rs 83 million compared to net profit of Rs 62 million during FY22. Revenue of the company grew 22.2% to Rs 1,396 million during FY23.
The current Price to earnings ratio of KILITCH DRUGS, based on rolling 12 month earnings, stands at 54.8.
Equitymaster requests your view! Post a comment on "KILITCH DRUGS Gains 6%; BSE HEALTHCARE Index Up 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!